Nuvisan has completed over 15 HTX projects across a diverse range of protein classes over the past year, achieving hit rates from 4% to 40% depending on target druggability.

Your partner of choice in bringing therapeutics to life, Nuvisan is the unique CRO/CDMO with extensive pharma experience and industry-leading scientific expertise, providing highest-quality end-to-end solutions. From enabling target understanding to helping get innovative medicines to the patients who need them, we provide support that streamlines and accelerates drug discovery and development.